WO2010124009A3 - Fully human anti-vegf antibodies and methods of using - Google Patents

Fully human anti-vegf antibodies and methods of using Download PDF

Info

Publication number
WO2010124009A3
WO2010124009A3 PCT/US2010/031921 US2010031921W WO2010124009A3 WO 2010124009 A3 WO2010124009 A3 WO 2010124009A3 US 2010031921 W US2010031921 W US 2010031921W WO 2010124009 A3 WO2010124009 A3 WO 2010124009A3
Authority
WO
WIPO (PCT)
Prior art keywords
vegf
fully human
methods
human anti
vegf antibodies
Prior art date
Application number
PCT/US2010/031921
Other languages
French (fr)
Other versions
WO2010124009A2 (en
Inventor
Sumant Ramachandra
Chin-Yi Huang
Linda Masat
Chao Bai Huang
Walter Robert Bishop
Toshihiko Takeuchi
Seema Kantak
Jo Ann Horowitz
Mohamed H. Ladha
Original Assignee
Schering Corporation
Xoma Technology Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation, Xoma Technology Ltd. filed Critical Schering Corporation
Publication of WO2010124009A2 publication Critical patent/WO2010124009A2/en
Publication of WO2010124009A3 publication Critical patent/WO2010124009A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen- binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.
PCT/US2010/031921 2009-04-21 2010-04-21 Fully human anti-vegf antibodies and methods of using WO2010124009A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17138009P 2009-04-21 2009-04-21
US61/171,380 2009-04-21

Publications (2)

Publication Number Publication Date
WO2010124009A2 WO2010124009A2 (en) 2010-10-28
WO2010124009A3 true WO2010124009A3 (en) 2011-01-06

Family

ID=43011738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/031921 WO2010124009A2 (en) 2009-04-21 2010-04-21 Fully human anti-vegf antibodies and methods of using

Country Status (1)

Country Link
WO (1) WO2010124009A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789138A (en) * 2016-10-04 2019-05-21 株式会社钟根堂 For treating the histone deacetylase inhibitor of hematologic cancers and the pharmaceutical composition of proteasome inhibitor or immunoregulation medicament

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1848414E (en) 2005-02-03 2011-05-25 Gen Hospital Corp Method for treating gefitinib resistant cancer
AR057854A1 (en) 2005-11-04 2007-12-19 Wyeth Corp ANTINEOPLASTIC COMBINATIONS WITH MTOR INHIBITOR, HERCEPTINE AND / OR HKI-272 (E) -N- {4- [3-CHLORINE-4- (2-PIRIDINILMETOXI) ANILINO] -3-CIANO-7-ETOXI-6-QUINOLINIL} -4- (DIMETHYLAMINE) -2-BUTENAMIDE
WO2008042236A2 (en) 2006-09-29 2008-04-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20180128078A (en) 2008-06-17 2018-11-30 와이어쓰 엘엘씨 Antineoplastic combinations containing hki-272 and vinorelbine
KR20140069340A (en) 2008-08-04 2014-06-09 와이어쓰 엘엘씨 Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN102369010A (en) 2009-04-06 2012-03-07 惠氏有限责任公司 Treatment regimen utilizing neratinib for breast cancer
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
DK2488204T3 (en) 2009-10-16 2016-06-06 Oncomed Pharm Inc Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
EP3485903B1 (en) 2011-09-23 2022-11-16 Mereo BioPharma 5, Inc. Vegf/dll4 binding agents and uses thereof
CN103664797A (en) * 2012-09-25 2014-03-26 杨子娇 Compounds for treating narrow chamber angle and application thereof
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
JP6371294B2 (en) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Methods and monitoring of treatment with DLL4 antagonists
US9388239B2 (en) * 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
KR20210125603A (en) 2014-06-16 2021-10-18 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Treating myelomas
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
WO2016057554A1 (en) * 2014-10-06 2016-04-14 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
AU2015338974B2 (en) 2014-10-31 2021-08-26 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
TW201707725A (en) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 Carrier-antibody compositions and methods of making and using the same
CN109071644B (en) 2015-09-23 2023-09-19 昂考梅德药品有限公司 Methods and compositions for treating cancer
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
AU2017238118A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
WO2017165440A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
JP6949106B2 (en) 2016-08-23 2021-10-13 メディミューン リミテッド Anti-VEGF-A antibodies and their use
EP4177271A1 (en) 2016-09-01 2023-05-10 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
CN109843336A (en) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 Method and composition for targeting T-cells cancer
MX2019002562A (en) 2016-09-06 2019-09-18 Mayo Found Medical Education & Res Methods of treating pd-l1 expressing cancer.
JP7025412B2 (en) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Paclitaxel-albumin-binder composition and method of use and production of the composition
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CN106929513A (en) * 2017-04-07 2017-07-07 东南大学 The nano antibody of mRNA codings and its application
CN108379566B (en) * 2018-02-01 2020-06-16 郑州大学 Tumor-like human umbilical vein endothelial cell vaccine and application thereof in cancer resistance

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133706A2 (en) * 2006-10-20 2008-11-06 Schering Corporation Fully human anti-vegf antibodies and methods of using
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133706A2 (en) * 2006-10-20 2008-11-06 Schering Corporation Fully human anti-vegf antibodies and methods of using
WO2009055343A2 (en) * 2007-10-22 2009-04-30 Schering Corporation Fully human anti-vegf antibodies and methods of using

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789138A (en) * 2016-10-04 2019-05-21 株式会社钟根堂 For treating the histone deacetylase inhibitor of hematologic cancers and the pharmaceutical composition of proteasome inhibitor or immunoregulation medicament

Also Published As

Publication number Publication date
WO2010124009A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
WO2010124009A3 (en) Fully human anti-vegf antibodies and methods of using
WO2009055343A3 (en) Fully human anti-vegf antibodies and methods of using
MX2009004027A (en) Fully human anti-vegf antibodies and methods of using.
PH12017500864A1 (en) Anti-notch1 antibodies
WO2012109373A3 (en) Treatment of osteoarthritis and pain
TN2009000529A1 (en) Methods and compositions for treating allergic diseases
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2012024650A3 (en) Anti-ngf antibodies and their use
IN2012DN00863A (en)
HK1194757A1 (en) Antibodies, variable domains & chains tailored for human use
WO2012162067A3 (en) Cd3-binding molecules capable of binding to human and non-human cd3
MY165273A (en) Anti-cd48 antibodies and uses thereof
EP2590671A4 (en) Dual variable domain immunoglobulins and uses thereof
AU2014227664A8 (en) Dual specific binding proteins directed against TNFalpha
MX2011011670A (en) Dual variable domain immunoglobulins and uses thereof.
MX2012005037A (en) Dual variable domain immunoglobulins and uses thereof.
MX2012004415A (en) Dual variable domain immunoglobulins and uses thereof.
SG178602A1 (en) Dual variable domain immunoglobulins and uses thereof
MX2012001262A (en) Dual variable domain immunoglobulins and uses thereof.
MX2011011669A (en) Dual variable domain immunoglobulins and uses thereof.
PL2917229T3 (en) Antibodies and fragments thereof raised against the alpha-3 domain of hla-g protein, methods and means for their preparation, and uses thereof
WO2012033987A3 (en) Anti-human folate receptor beta antibodies and methods of use
TW200736275A (en) Methods and compositions for treating allergic diseases
WO2011163478A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2013102042A3 (en) Dual variable domain immunoglobulins against il-13 and/or il-17

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10767714

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10767714

Country of ref document: EP

Kind code of ref document: A2